News | November 20, 2007

New LVAD Testing in 10 U.S. Hospitals

November 21, 2007 - Ventracor announced 10 U.S. hospitals have implanted at least one VentrAssist left ventricular assist device (LVAD) as part of its U.S. clinical trials, as part of the company’s strategy to penetrate the U.S. VAD market.

The VentrAssist implantable blood pump is designed for long-term use, and the longest duration implant is now over three years. As part of the Company's US Bridge-to-Transplant (BTT) Pivotal Trial, which involves approximately 140 patients, 18 patients have been implanted in the U.S. The trial aims to evaluate the safety and efficacy of the VentrAssist for short-term use in patients whose heart deteriorates before a donor heart is available for transplant.

Eight patients have been enrolled in the US Destination Therapy (DT) Trial out of approximately 225 enrollments for the trial. The randomized trial is designed to evaluate the safety and efficacy of long-term use of the VentrAssist in patients with heart failure who are not candidates for a heart transplant. There have now been 172 implants at 24 hospitals worldwide, with over 83 years of cumulative patient experience.

The company has developed a new version, the VentrAssist LVA4, which will be introduced in all markets as soon as approval is obtained in response to the regulatory submissions already made.

For more information:

Related Content

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Overlay Init